{"a":[{"_":"Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’","$":{"href":"/biotech/ultragenyx-fails-phase-3-angelman-test-plots-significant-expenses-reduction","hreflang":"en"}}]}
Phase 3negativeGenglycosNegative
AI Analysis
Summary
Ultragenyx announced a Phase 3 trial failure for an Angelman syndrome treatment candidate. The company plans significant expense reductions following the negative data.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Phase 3 trial failure in Angelman syndrome indication
Importance:8/10
Sentiment:
-0.90
Phase 3 failureAngelman syndromeCost reductionClinical trial
Related Companies
Read the original article
Published by FierceBiotech on September 3, 2026 2:40 AM